CD4⁺, IL17 and Foxp3 Expression in Different pTNM Stages of Operable Non-small Cell Lung Cancer and Effects on Disease Prognosis

The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review

“…Liver cancer, colorectal cancer, and non-small cell lung cancer seem to be correlated with an unfavorable IL-17 response. 15,16,[18][19][20][24][25][26][40][41][42][43][44][45][46] Leukemia on the other hand might provide an environment favorable for Th17 cells to suppress tumor growth. 32,38 Similarly, ovarian cancer might attract a tumor suppressing IL-17 response, as the majority of studies found a correlation with a favorable outcome.…”

“…CLL D chronic lymphocytic leukemia; AC D adenocarcinoma; CRC D colorectal carcinoma; HCC D hepatocellular carcinoma; NA D not applicable or not mentioned in the article; NSCLC D non-small cell lung carcinoma. 15,16,[18][19][20]30,37,[40][41][42][43][44][45][46][47][48][49][50] Five studies reported on a correlation between a high number of IL-17 C cells and improved survival. 21,28,29,51,52 It is important to note that in two of these five studies, the IL-17 C cells were scored in areas with the densest lymphocytic infiltrate, one of which was on pancreatic ductal adenocarcinoma patients who had received immunotherapy (the correlation between IL-17 and survival was based on 12 patients).…”

Association between Polymorphisms of Interleukin-17A and Interleukin-17F Genes and Silicosis Susceptibility in Chinese Han People

“…Interleukin17 (IL-17) is a primary effector secreted from Th17 cells which is considered to be a group of important induce inflammatory reaction cells (Gaffen et al, 2008). The important members of IL-17 family are IL-17A and IL-17F, and the main biological function of IL-17 is promoting the inflammatory reaction (Han et al, 2009;Zhang et al, 2012;Fang et al, 2012). IL-17 is not only associated with chronic inflammation, but also promots the formation of pulmonary fibrosis.…”

Anti-cancer activity of dose-fractioned mPE +/− bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

“…T reg s, whose activation is under control of CTLA-1 checkpoint, have the specific ability to attenuate the extent of cancer associate immuneresponse and represents a common mechanism of immuneescape for cancer cells (26)(27)(28)(29). IL-17A is able to promote A B the switch of inactive T reg s in highly suppressive subsets that, in turn, can inhibit all the attempts of immune-system and tumor-specific CTLs to counteract tumor growth and development (29)(30)(31)(32) another very active CTL subset expressing the L selectin (CD62L), a trans-membrane protein which allows the binding to the specific receptor on tumor vessels and the consequent extravasation in the tumor sites (37). In our patients, we also found a significant increase of peripheral DCs expressing CD83 and CD80, a very efficient antigen presenting cell linage able to uptake and process antigen released by tumor tissues exposed to the cytotoxic drugs (38).…”